Androgen regulation of ETS gene fusion transcripts in prostate cancer.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Methods in molecular biology

• Publication date

  2011-09-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-1-61779-243-4_19PMID 21796535
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.

  2009cited by this paper
• Chimeric transcript discovery by paired-end transcriptome sequencing

  2009cited by this paper
• Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays.

  2008cited by this paper
• TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis

  2008cited by this paper
• ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer

  2008cited by this paper
• Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.

  2008cited by this paper
• A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.

  2008cited by this paper
• Skp2 is an independent prognosticator of gallbladder carcinoma among p27Kip1-interacting cell cycle regulators: an immunohistochemical study of 62 cases by tissue microarray

  2007cited by this paper
• A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis

  2007cited by this paper
• Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer

  2007cited by this paper
• TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

  2007cited by this paper
• Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

  2006cited by this paper
• TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.

  2006cited by this paper
• TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

  2006cited by this paper
• Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer.

  2006cited by this paper
• TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.

  2006cited by this paper
• Transcription factors in cancer

  2005cited by this paper
• ETS transcription factors and their emerging roles in human cancer.

  2005cited by this paper
• Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer

  2005cited by this paper

• The relevance of ERG immunoexpression intensity for prostatic adenocarcinoma in radical prostatectomy of 635 samples.

  2023cites this paper
• Research progress in the mechanism of TMPRSS2-ERG fusion gene in prostate cancer

  2017cites this paper
• 12‐HETER1/GPR31, a high‐affinity 12(S)‐hydroxyeicosatetraenoic acid receptor, is significantly up‐regulated in prostate cancer and plays a critical role in prostate cancer progression

  2016cites this paper
• Nuclear targeting of dystroglycan promotes the expression of androgen regulated transcription factors in prostate cancer

  2013cites this paper
• Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer

  2013cites this paper
• Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause‐specific mortality

  2013cites this paper